Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 3Active not recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lung Neoplasms 9Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillary renal cell carcinoma, sporadic 1Pancreatic Neoplasms 1

Interventions

Rituximab 39Cyclophosphamide 35Magnetic Resonance Spectroscopy 22Specimen Handling 20Doxorubicin 18polatuzumab vedotin 17Prednisone 17Lenalidomide 15Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13zanubrutinib 11Vincristine 11Immunotherapy, Adoptive 10Etoposide 10glofitamab 9axicabtagene ciloleucel 7Prednisolone 7obinutuzumab 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6Bendamustine Hydrochloride 6loncastuximab tesirine 5ibrutinib 5acalabrutinib 5Carboplatin 5CT-P10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × Disulfides × Clear all
NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

University of Washington

Phase 1/2 Recruiting
35 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
37 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

SWOG Cancer Research Network

Phase 2 Recruiting
227 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡